This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/3/424    most recent ATVBAHA.108.181735v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray, K. K. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Ray, K. K. Articles by Braunwald, E. Related Collections Secondary prevention Acute coronary syndromes Epidemiology Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:424.)
© 2009 American Heart Association, Inc.

Clinical and Population Studies

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes

Results From PROVE IT–TIMI 22

Kausik K. Ray; Christopher P. Cannon; Richard Cairns; David A. Morrow; Paul M Ridker; Eugene Braunwald

From the TIMI Study Group, Cardiovascular Division and the Department of Medicine (C.P.C., D.A.M., E.B.), Brigham and Women’s Hospital/Harvard Medical School, Boston, Mass; the Department of Public Health and Primary Care (K.K.R.), University of Cambridge, UK; Worldwide Clinical Trials (R.C.), and the Donald W. Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention (P.M.R.), Brigham and Women’s Hospital, Boston, Mass.

Correspondence to Christopher P. Cannon, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail cpcannon{at}partners.org

Objectives— The purpose of this study was to compare the prognostic utility of apoB/AI, total cholesterol/HDL (TC/HDL) ratio, non-HDL cholesterol (non–HDL-C), or hs-CRP as predictors of clinical risk among patients receiving statin therapy after acute coronary syndromes (ACS).

Methods and Results— Patients with ACS were randomized in the PROVE IT–TIMI 22 trial to either pravastatin 40 mg or atorvastatin 80 mg. Cox regression models adjusting for confounders were used to assess the relationship between on-treatment lipids or hs-CRP and risk of death or acute coronary events. At 4 months a 1 SD increment in apoB/AI (HR 1.10, 95% CI 1.01 to 1.20), TC/HDL (HR 1.12, 95% CI 1.01 to 1.24), and non–HDL-C (HR 1.20, 95% CI 1.07 to 1.35) predicted events to a similar extent as LDL-C (HR 1.20, 95% CI 1.07 to 1.35) with neither apoB/AI, TC/HDL, nor non–HDL-C improving risk prediction models which included LDL-C. In contrast, the addition of hs-CRP significantly improved risk prediction models irrespective of the lipid parameters included, with a 29% to 30% increased risk observed per 1 SD increment in log CRP.

Conclusion— In the present study of ACS patients receiving statin therapy, on-treatment apoB/AI, TC/HDL, and non–HDL-C offered similar prognostic information to LDL-C. However, the addition of hs-CRP to lipid-based measurements significantly improved risk prediction. On treatment CRP measurement may therefore offer additive prognostic information to lipids in ACS patients.

In this analysis from PROVE IT–TIMI 22, on-treatment apoB/AI, TC/HDL, and non–HDL-C offered similar prognostic information to LDL-C. However, the addition of hs-CRP to lipids significantly improved risk prediction.

Key Words: statins • apolipoprotein • inflammation • CRP • CHD

This article has been cited by other articles:

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555. [Full Text] [PDF]